Market Access Biotech funding has returned. The bar has moved with it. For biotech sponsors, the question worth asking is not whether the rebound is real, but what it is actually rewarding.
Market Access Capital discipline in biotech: Building enduring companies w... Capital depends on the strength of the science, the quality of execution, and the ability to deliver on milestones as planned.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia last month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
News Despite US policy changes, drug prices stay stubbornly high US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.